打开APP

Infinity支付1500万美元与Takeda达成合作协议

  1. Infinity
  2. Takeda
  3. 药物研发许可协议

来源:生物谷 2013-01-05 10:54

2012年12月29日讯 /生物谷BIOON/ -- Infinity公司已经与Takeda旗下Millennium达成许可协议。Infinity公司将向Takeda公司支付1500万美元并向millennium公司支付500万美元来获得IPI-145的研发项目。 Infinity公司在其标志性药品saridegib研究失败后遭受重创。

2012年12月29日讯 /生物谷BIOON/ -- Infinity公司已经与Takeda旗下Millennium达成许可协议。Infinity公司将向Takeda公司支付1500万美元并向millennium公司支付500万美元来获得IPI-145的研发项目。

Infinity公司在其标志性药品saridegib研究失败后遭受重创。公司副总裁,CFO Lawrence Bloch, M.D., J.D表示该项目前景良好,并认为IPI-145作为一种PI3K抑制剂药物有着极大的市场潜力。(生物谷Bioon.com)

详细英文报道:

Lining up squarely behind its new lead drug, Infinity Pharmaceuticals ($INFI) has tailored its licensing deal with Takeda's Millennium. The Cambridge, MA-based biotech has agreed to pay Takeda $15 million and in exchange Millennium is ripping up its option to bag a 50/50 split on any of Infinity's PI3K inhibitors, including the lead program for IPI-145. Infinity also announced that it paid Millennium a $5 million development milestone for the August 2012 launch of the Phase IIa clinical trial of IPI-145 in patients with asthma.

Infinity has been forced to restructure over the course of 2012 after its original lead drug saridegib failed a slate of clinical trials. Infinity, a 2005 Fierce 15 company, scooped up the global development and commercialization rights to a portfolio of oral PI3K inhibitors developed by Intellikine back in the summer of 2010. And late last year Takeda acquired Intellikine and its business deals in a $310 million buyout pact.

"We believe that the potency of IPI-145 against both PI3K-delta and PI3K-gamma contribute to its potential to become the best-in-class PI3K inhibitor," stated Lawrence Bloch, M.D., J.D., executive vice president, chief financial officer and chief business officer of Infinity. "Infinity is focused on rapidly advancing IPI-145 and additional follow-on PI3K product candidates with the goal that patients, our shareholders and other financial stakeholders, including Millennium, will benefit from their development and commercialization."

"We have had a successful relationship with Infinity since the December 2011 acquisition of Intellikine by Takeda Pharmaceutical Company Limited," said Kyle Kuvalanka, vice president, business development and corporate strategy and development of Millennium. "We look forward to Infinity's continued progress and to participating in the downstream value of its PI3K program through future milestone and royalty payments."

 

版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不得转载,否则将追究法律责任。取得书面授权转载时,须注明“来源:生物谷”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。

87%用户都在用生物谷APP 随时阅读、评论、分享交流 请扫描二维码下载->